Toronto, A6CIK 16226274 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
29 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Delcath Sys Inc | 3.30M | $33.00M | 12.0% | 0 | Held |
| 2 | Savara Inc | 3.40M | $20.52M | 7.5% | −596.3K | Reduced |
| 3 | Fennec Pharmaceuticals Inc | 2.61M | $20.12M | 7.3% | +536.7K | Added |
| 4 | Xeris Biopharma Holdings Inc |
| 2.11M |
| $16.58M |
| 6.0% |
| +315.9K |
| Added |
| 5 | Viridian Therapeutics Inc | 450.0K | $14.00M | 5.1% | −150.0K | Reduced |
| 6 | Mediwound Ltd | 749.1K | $13.83M | 5.0% | 0 | Held |
| 7 | Verastem Inc | 1.79M | $13.81M | 5.0% | −141.1K | Reduced |
| 8 | Replimune Group Inc | 1.41M | $13.71M | 5.0% | +1.41M | New |
| 9 | Atyr Pharma Inc | 1.04M | $13.60M | 5.0% | 0 | Held |
| 10 | Cybin Inc | 1.66M | $13.56M | 4.9% | +157.5K | Added |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio